Abeona Therapeutics Aktie 28637123 / US00289Y1073
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
11.11.2025 05:19:36
|
KalVista, Health Catalyst, Bio-Techne Lead After-Hours Gains On Earnings Updates
(RTTNews) - Several healthcare and biotech stocks posted notable gains in Monday's after-hours trading following earnings updates and guidance revisions.
KalVista Pharmaceuticals Inc. (KALV) rose 11.29% to $12.12 after hours, building on a modest 1.02% gain at the close. The company reported a third-quarter net loss of $49.5 million, or $0.92 per share, compared to a loss of $39.1 million, or $0.84 per share, in the same period last year. Net product revenue for the quarter reached $13.7 million.
Health Catalyst Inc. (HCAT) advanced 13.24% to $3.23 after hours, following a 0.71% increase during regular trading. The company posted a third-quarter net loss of $22.2 million, or $0.32 per share, versus $14.7 million, or $0.24 per share, a year ago. Revenue declined to $76.3 million from $86.4 million.
For Q4 2025, the company projects revenue of about $73.5 million and adjusted EBITDA of $13.4 million. Full-year expectations stand at $310 million in revenue and $41 million in adjusted EBITDA.
Bio-Techne Corp. (TECH) climbed 8.72% to $62.47 in after-hours trading. No new announcements were made on Monday, but the company recently reported first-quarter GAAP EPS of $0.24, up from $0.21 last year. Adjusted EPS remained flat at $0.42. Revenue declined 1% year-over-year to $286.6 million.
Assertio Holdings Inc. (ASRT) gained 8.30% to $0.87 after hours, adding to a 5.33% increase at the close. The company reported third-quarter GAAP net income of $11.4 million, or $0.11 per share, compared to a loss of $2.9 million, or $0.03 per share, last year. Adjusted EPS rose to $0.18 from $0.02. Net product sales reached $49.5 million, up from $28.7 million.
Assertio narrowed its full-year 2025 guidance, projecting net product sales between $110 million and $112 million, and adjusted EBITDA between $14 million and $16 million.
Abeona Therapeutics Inc. (ABEO) moved up 8.51% to $4.59 in after-hours trading. The company did not release news Monday but is scheduled to report third-quarter results on November 12. Analysts expect a loss of $0.34 per share on revenue of $5.53 million.
Analysen zu Abeona Therapeutics Inc
Im BX Morningcall werden folgende Aktien analysiert und erklärt
✅ Parker-Hannifin
✅ JPMorgan Chase
✅ Dollarama
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Bio-Techne Corp | 53.00 | 0.00% |
|
| Health Catalyst Inc Registered Shs | 2.14 | -0.93% |
|
| KalVista Pharmaceuticals Inc | 11.30 | -0.88% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX fester erwartet -- Asiens Börsen in GrünAm heimischen sowie am deutschen Aktienmarkt werden am Donnerstag moderate Gewinne erwartet. In Fernost geht es am Donnerstag aufwärts.